Pergolide Market

Pergolide Market Size, Share & Industry Analysis, By Source (In-house Pharmaceutical API Manufacturers, Contract Manufacturing Organizations (CMOs), Specialty API Suppliers, Research-Based Bulk API Producers), By End-Use Industry (Pharmaceutical Companies, Neurology Clinics & Hospitals, Contract Development & Manufacturing Organizations (CDMOs), Research & Academic Institutions), and Forecast, 2025–2035

The global Pergolide market is projected to grow at a CAGR of 4.6% from 2025 to 2035. This growth is primarily driven by the rising prevalence of Parkinson’s disease, especially among aging populations, and the increasing use of dopamine receptor agonists in neurology. Additionally, Pergolide is widely used in veterinary medicine, particularly for managing equine Cushing’s disease (pituitary pars intermedia dysfunction – PPID), further supporting its demand.

Regionally, North America and Europe are expected to dominate the Pergolide API market, supported by well-established neurological care infrastructure and significant demand for advanced Parkinson’s therapies. Meanwhile, the Asia-Pacific region is projected to experience the fastest growth, driven by improved healthcare access, rising elderly populations, and expanding pharmaceutical manufacturing in countries like India and China.

The market report highlights advancements in API production, such as improved chiral synthesis, cost-effective manufacturing pathways, and veterinary-grade API development. However, the market faces challenges such as regulatory restrictions, limited awareness in certain regions, and competition from newer dopamine agonists. Despite this, the growing need for reliable neurological and veterinary treatments is expected to sustain steady growth in the Pergolide API market over the forecast period.

Seeking Comprehensive Intelligence on Different markets? Get in Touch with our Experts

Report Scope & Segmentation

  1. Introduction
  • Overview of Pergolide
  • Key End-Users & Industry Use Cases
  • Market Scope & Study Objectives
  1. Market Overview
  • Global Market Size & Growth Trends (Historical & Forecast)
  • Demand-Supply Dynamics
  1. Segmental Outlook
  • By Source
    • In-house Pharmaceutical API Manufacturers
    • Contract Manufacturing Organizations (CMOs)
    • Specialty API Suppliers
    • Research-Based Bulk API Producers
  • Key End-Use Industries
  • Pharmaceutical Companies
  • Neurology Clinics & Hospitals
  • Contract Development & Manufacturing Organizations (CDMOs)
  • Research & Academic Institutions
  1. Price Analysis
  • Current Price Trends (Per kg & Per Ton)
  • Price Fluctuation Factors (Raw Material Costs, Production, Trade Tariffs)
  • Regional Price Comparison (North America, Europe, Asia-Pacific, and Other)
  1. Trade Analysis
  • Major Exporting & Importing Countries
  • Trade Volume & Value Statistics
  • Impact of Trade Regulations & Policies
  1. Regional Analysis
  • North America (US and Canada)
  • Europe (UK, Germany, France, Italy, Spain, and the Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea, Taiwan, India, and Rest of Asia-Pacific)
  • Rest of the World (Latin America, and Middle East, and Africa)
  1. Competitive Landscape
  • Top Global Manufacturers & Production Capacity
  • Company Profiles & Key Developments
    • Teva Pharmaceutical Industries Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Dr. Reddy’s Laboratories
    • LGM Pharma
    • Cipla Ltd.
    • Alkem Laboratories Ltd.
    • Aurobindo Pharma
    • Jubilant Pharmova
    • Apicore LLC
    • MSN Laboratories
    • Hetero Drugs Ltd.
    • Mac-Chem Products (India) Pvt. Ltd.
    • Shreeji Pharma International
    • Amneal Pharmaceuticals
    • Glenmark Pharmaceuticals
    • Ipca Laboratories
    • Neuland Laboratories
    • Cambrex Corporation
    • Olon S.p.A
    • Shandong Xinhua Pharmaceutical Co., Ltd.
  • Mergers, Acquisitions & Investments
  1. Regulatory & Compliance Factors
  • FDA, REACH, and Other Regulatory Frameworks
  • Environmental & Safety Considerations
  • Emerging Policies Impacting Market Growth
  1. Conclusion & Strategic Recommendations
  • Key Takeaways for Stakeholders
  • Market Entry Strategies
What is a Pergolide?
Pergolide is a dopamine receptor agonist used primarily in the treatment of Parkinson’s disease and hyperprolactinemia. It is also widely prescribed in veterinary medicine for treating equine Cushing’s disease (PPID).
What is the market size for Pergolide?
The global Pergolide API market is projected to grow at a CAGR of 4.6% between 2025 and 2035. Growth is supported by increasing cases of neurological disorders, expanded veterinary applications, and demand for generic alternatives in both human and animal health sectors.
What are the drivers for Pergolide?
Key drivers include the rising prevalence of Parkinson’s disease, growing awareness of hormonal and neurological disorders, and increased use of Pergolide in the veterinary sector for treating PPID in horses. The demand for cost-effective, long-acting dopamine agonists also boosts the market.
Who are the key players operating in the Pergolide Market?
Major players include Teva Pharmaceuticals, Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, LGM Pharma, Cipla Ltd., Alkem Laboratories, and Hetero Drugs Ltd.
Which region would exhibit the fastest growth in the Pergolide Market?
The Asia-Pacific region is expected to witness the fastest growth due to rising elderly populations, improved veterinary services, and expanding pharmaceutical manufacturing in countries like India and China.
$1800/- Single User License
$3600/- Multi User License

How can we help you?

Reach out to discuss how our team can help your business achieve real results.